Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
Terminated
Phase 3 Results N/ASummary of Purpose
The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months. Trial Stopped: Futility
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 21 December 2009.
1 Sep 2005 | 30 Aug 2005 | 1 Dec 2008 | 1 Dec 2008 | 1 Dec 2009 | Unavailable |
Start Date | First Received | 1st Completion | Completion | Verification | Results |
---|
Trial Basics
Interventions
Conditions
Sponsors
Trial Design
- Allocation: Randomized
- Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
Contacts
-
Vicki Higham Phone: 201-941-8807, E-mail: vhigham@ntii.com
vhigham@ntii.com
View Trial Locations
Recruitment
- Enrollment: 277
- Gender: Both
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 100 locations, 10 countries
Principal Investigator
- Warren Wasiewski, M.D.
Neurobiological Technologies